ArticleGastroenterology and hepatology from bed to bench2025
Preventive and therapeutic effects of cepharanthine on acetaminophen-induced acute liver and kidney injury in male laboratory mice.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to evaluate the preventive and therapeutic effects of cepharanthine on APAP (N-acetyl-para-aminophenol )-induced liver and kidney injury in an experimental model. Background: Acetaminophen (APAP) is widely used as an analgesic and antipyretic drug; however, its overdose can cause acute liver and kidney injury. Cepharanthine, a natural alkaloid with antioxidant properties, has been proposed as a potential protective agent. Methods: In this experimental study 40 Male NMRI mice were divided into five groups: Control, Sham, APAP-treated, APAP + preventive cepharanthine, and APAP + therapeutic cepharanthine groups. Liver and kidney function markers, including ALT, AST, BUN, creatinine, total antioxidant capacity (TAC), and malondialdehyde (MDA), were measured. Histopathological analysis was performed to assess tissue damage. Statistical analysis was conducted using ANOVA with a significance threshold of p < 0.05. Results: APAP administration significantly increased ALT, AST (p < 0.001), and MDA (p < 0.01) while reducing TAC levels (p < 0.01) in liver and kidney tissues. Cepharanthine, particularly in the therapeutic group, reduced ALT levels (p < 0.05) and improved liver histology but did not significantly alter AST or TAC in the prevention group. In contrast, cepharanthine failed to improve kidney function markers and worsened histological damage, leading to increased tubular casts and hemorrhagic areas. Conclusion: Cepharanthine exhibited partial hepatoprotective effects against APAP-induced liver injury but did not improve kidney damage. So, this natural alkaloid does not confer a significant protective effect against acute kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.